Clinical trial NCT00599131: Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
Official title: A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cancer of Larynx
Keywords: Cancer of Larynx
Lead sponsor: University of Michigan Rogel Cancer Center
Sponsor class: OTHER
First posted: 2008-01-23
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn how to identify early which patients will respond to chemotherapy plus radiation therapy in order to reduce the number of subjects who require surgery (followed by radiation therapy).

Detailed description: In this study one cycle of chemotherapy will be administered and then those subjects who respond well to that cycle will be started on radiation therapy along with chemotherapy and those that don't respond well to the initial cycle of chemotherapy, will undergo a total laryngectomy (surgery to remove the voice box) followed by radiation therapy. The initial cycle of chemotherapy consists of the drugs Taxotere, Cisplatin, and 5-Fluorouracil (this combination is known as TPF). Then on Day 20 of the study, the subjects will be administered another chemotherapy agent called cetuximab (a.k.a. C-225). It will then be determined if the patient's response to the chemotherapy was favorable by examining the patient's tumor with an endoscopy. If the response is determined to be good, then the patient will continue with a chemotherapy regimen with the addition of radiation therapy combination. If the patient's response to the chemotherapy is determined to be less than favorable, then the patient will be advised to undergo salvage surgery (a.k.a. laryngectomy) to remove their voice box and then undergo radiation therapy treatment. Additionally, tumor tissue samples and blood will be studied to see if there are special molecular markers that help predict when a tumor will respond to chemotherapy and radiation treatment.

Eligibility criteria: Inclusion Criteria:

* Patients must have pathologically confirmed, previously untreated, resectable, squamous cell carcinoma of the larynx.
* Disease must be Stage III or IV.
* Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy.
* Patients must undergo pre-treatment endoscopic tumor staging and CT scanning.
* ECOG Performance status 0-2
* Pre-treatment laboratory criteria:
* WBC \> or = to 3500/ul, granulocyte \> or = to 1500/ul.
* Platelet count \> or equal to 100,000/ul.
* Calculated or measured creatinine clearance \> or = to 60 cc/min.
* Total Bilirubin \< or = to 1.5 X ULN.
* AST and ALT \< or = to 2.5 X ULN.
* Patients must give documented informed consent to participate in this study.

Exclusion Criteria:

* Prior head and neck malignancy or history of other prior non-head and neck malignancy within the past 3 years.
* Prior head and neck radiation or prior chemotherapy.
* Documented evidence of distant metastases.
* Active infection.
* Pregnancy or lactation. Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
* Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patients ability to tolerate this treatment.
* Patients residing in prison.
* Age \< 18 years.
* Patients with psychiatric/social situations that would limit compliance with study requirements are not eligible.
* Patients with prior radiation to the head and neck.
* Patients with prior anti-epidermal growth-factor receptor antibody therapy or therapy with a tyrosine-kinase inhibitor.
* Patients with Grade \> 2 peripheral neuropathy.
* Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.

Primary outcomes:
measure: Percentage of Patients Achieving Histologic Complete Response
timeFrame: 3 years
Secondary outcomes:
measure: The Difference, From Baseline, in EGFR, for Tumor Biopsies Taken After the Administration of Cetuximab Following TPF.
timeFrame: Day 23
measure: The Change in Overall Quality of Life Score During Radiation Therapy and at 6, 12, and 24 Months Post Treatment.
timeFrame: 24 months
measure: Overall Survival Time
timeFrame: 3 years
measure: The Number of Patients That Experience Grade 3 and 4 Mucositis or Dysphagia
timeFrame: 3 years.
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Comprehensive Cancer Center
state: Michigan
Study officials:
affiliation: University of Michigan
name: Francis P. Worden, M.D.
role: PRINCIPAL_INVESTIGATOR
References: